An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy.

T. Hara, J. Nakamura, N. Koh, F. Sakakibara, Y. Hamada, H. Sasaki, Keiji Naruse, E. Nakashima, N. Takeuchi, S. Inukai

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

To investigate the relationship between metabolic and vascular factors, especially polyol pathway and platelet aggregation, in the pathogenesis of diabetic neuropathy, the effects of a novel potent aldose reductase inhibitor, TAT ((5-(3-thienyl) tetrazol-1-yl) acetic acid monohydrate) on adenosine diphosphate-induced platelet aggregation, polyol contents in platelets, motor nerve conduction velocity (MNCV), and sciatic nerve blood flow (SNBF) were examined in streptozotocin-induced diabetic rats. Diabetic rats demonstrated hyperaggregation in response to adenosine diphosphate, accompanied by sorbitol and fructose accumulation and myoinositol depletion in platelets. Treatment with TAT improved these abnormalities in diabetic rats. A delayed MNCV and a reduced SNBF in diabetic rats were normalized by the administration of TAT. These observations suggest that increased polyol pathway activity plays an important role in platelet aggregation in the development of diabetic neuropathy and that aldose reductase inhibitor is useful for the treatment of diabetic neuropathy from the viewpoint not only of metabolic factors but also of vascular factors.

Original languageEnglish
Pages (from-to)541-547
Number of pages7
JournalJournal of Laboratory and Clinical Medicine
Volume126
Issue number6
Publication statusPublished - Dec 1995
Externally publishedYes

Fingerprint

Aldehyde Reductase
Streptozocin
Platelets
Adenosine Diphosphate
Diabetic Neuropathies
Rats
Blood Platelets
Platelet Aggregation
Neural Conduction
Sciatic Nerve
Agglomeration
Blood
Sorbitol
Inositol
Fructose
polyol
vascular factor
(5-(3-thienyl)tetrazol-1-yl)acetic acid

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy. / Hara, T.; Nakamura, J.; Koh, N.; Sakakibara, F.; Hamada, Y.; Sasaki, H.; Naruse, Keiji; Nakashima, E.; Takeuchi, N.; Inukai, S.

In: Journal of Laboratory and Clinical Medicine, Vol. 126, No. 6, 12.1995, p. 541-547.

Research output: Contribution to journalArticle

Hara, T, Nakamura, J, Koh, N, Sakakibara, F, Hamada, Y, Sasaki, H, Naruse, K, Nakashima, E, Takeuchi, N & Inukai, S 1995, 'An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy.', Journal of Laboratory and Clinical Medicine, vol. 126, no. 6, pp. 541-547.
Hara, T. ; Nakamura, J. ; Koh, N. ; Sakakibara, F. ; Hamada, Y. ; Sasaki, H. ; Naruse, Keiji ; Nakashima, E. ; Takeuchi, N. ; Inukai, S. / An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy. In: Journal of Laboratory and Clinical Medicine. 1995 ; Vol. 126, No. 6. pp. 541-547.
@article{d71b238c758344ebbb713c671e7d7457,
title = "An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy.",
abstract = "To investigate the relationship between metabolic and vascular factors, especially polyol pathway and platelet aggregation, in the pathogenesis of diabetic neuropathy, the effects of a novel potent aldose reductase inhibitor, TAT ((5-(3-thienyl) tetrazol-1-yl) acetic acid monohydrate) on adenosine diphosphate-induced platelet aggregation, polyol contents in platelets, motor nerve conduction velocity (MNCV), and sciatic nerve blood flow (SNBF) were examined in streptozotocin-induced diabetic rats. Diabetic rats demonstrated hyperaggregation in response to adenosine diphosphate, accompanied by sorbitol and fructose accumulation and myoinositol depletion in platelets. Treatment with TAT improved these abnormalities in diabetic rats. A delayed MNCV and a reduced SNBF in diabetic rats were normalized by the administration of TAT. These observations suggest that increased polyol pathway activity plays an important role in platelet aggregation in the development of diabetic neuropathy and that aldose reductase inhibitor is useful for the treatment of diabetic neuropathy from the viewpoint not only of metabolic factors but also of vascular factors.",
author = "T. Hara and J. Nakamura and N. Koh and F. Sakakibara and Y. Hamada and H. Sasaki and Keiji Naruse and E. Nakashima and N. Takeuchi and S. Inukai",
year = "1995",
month = "12",
language = "English",
volume = "126",
pages = "541--547",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy.

AU - Hara, T.

AU - Nakamura, J.

AU - Koh, N.

AU - Sakakibara, F.

AU - Hamada, Y.

AU - Sasaki, H.

AU - Naruse, Keiji

AU - Nakashima, E.

AU - Takeuchi, N.

AU - Inukai, S.

PY - 1995/12

Y1 - 1995/12

N2 - To investigate the relationship between metabolic and vascular factors, especially polyol pathway and platelet aggregation, in the pathogenesis of diabetic neuropathy, the effects of a novel potent aldose reductase inhibitor, TAT ((5-(3-thienyl) tetrazol-1-yl) acetic acid monohydrate) on adenosine diphosphate-induced platelet aggregation, polyol contents in platelets, motor nerve conduction velocity (MNCV), and sciatic nerve blood flow (SNBF) were examined in streptozotocin-induced diabetic rats. Diabetic rats demonstrated hyperaggregation in response to adenosine diphosphate, accompanied by sorbitol and fructose accumulation and myoinositol depletion in platelets. Treatment with TAT improved these abnormalities in diabetic rats. A delayed MNCV and a reduced SNBF in diabetic rats were normalized by the administration of TAT. These observations suggest that increased polyol pathway activity plays an important role in platelet aggregation in the development of diabetic neuropathy and that aldose reductase inhibitor is useful for the treatment of diabetic neuropathy from the viewpoint not only of metabolic factors but also of vascular factors.

AB - To investigate the relationship between metabolic and vascular factors, especially polyol pathway and platelet aggregation, in the pathogenesis of diabetic neuropathy, the effects of a novel potent aldose reductase inhibitor, TAT ((5-(3-thienyl) tetrazol-1-yl) acetic acid monohydrate) on adenosine diphosphate-induced platelet aggregation, polyol contents in platelets, motor nerve conduction velocity (MNCV), and sciatic nerve blood flow (SNBF) were examined in streptozotocin-induced diabetic rats. Diabetic rats demonstrated hyperaggregation in response to adenosine diphosphate, accompanied by sorbitol and fructose accumulation and myoinositol depletion in platelets. Treatment with TAT improved these abnormalities in diabetic rats. A delayed MNCV and a reduced SNBF in diabetic rats were normalized by the administration of TAT. These observations suggest that increased polyol pathway activity plays an important role in platelet aggregation in the development of diabetic neuropathy and that aldose reductase inhibitor is useful for the treatment of diabetic neuropathy from the viewpoint not only of metabolic factors but also of vascular factors.

UR - http://www.scopus.com/inward/record.url?scp=0029442425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029442425&partnerID=8YFLogxK

M3 - Article

C2 - 7490513

AN - SCOPUS:0029442425

VL - 126

SP - 541

EP - 547

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 6

ER -